Breast Cancer (MK-3475-756/KEYNOTE-756)

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

Condition: Early-Stage ER+/HER2- Breast Cancer | Last Updated: September 2019 | Status: Recruiting

View Full Study